GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » Dividend Yield %

Jasper Therapeutics (Jasper Therapeutics) Dividend Yield % : 0.00% (As of May. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics Dividend Yield %?

As of today (2024-05-04), the Trailing Annual Dividend Yield of Jasper Therapeutics is 0.00%.

The historical rank and industry rank for Jasper Therapeutics's Dividend Yield % or its related term are showing as below:

JSPR's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.49
* Ranked among companies with meaningful Dividend Yield % only.

Jasper Therapeutics's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00.

As of today (2024-05-04), the Forward Dividend Yield % of Jasper Therapeutics is 0.00%.

Jasper Therapeutics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Jasper Therapeutics Dividend Yield % Historical Data

The historical data trend for Jasper Therapeutics's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics Dividend Yield % Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Dividend Yield %
- - - -

Jasper Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Jasper Therapeutics's Dividend Yield %

For the Biotechnology subindustry, Jasper Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jasper Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's Dividend Yield % falls into.



Jasper Therapeutics Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Jasper Therapeutics  (NAS:JSPR) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Jasper Therapeutics Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jasper Therapeutics (Jasper Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Executives
Thomas G Wiggans director
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jeetinder Singh Mahal officer: Chief Operating Officer C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Ron Martell director, officer: President, CEO & Director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker officer: Chief Medical Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French director C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster director, 10 percent owner 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Gary E Rieschel 10 percent owner
Qiming U.s. Healthcare Fund Ii, L.p. 10 percent owner 350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade 10 percent owner C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Jasper Therapeutics (Jasper Therapeutics) Headlines

From GuruFocus

Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock

By Stock market mentor Stock market mentor 01-25-2023